How can I benefit from ADCETRIS?
Before making decisions about your treatment, see how others have responded to ADCETRIS
Select each tab to see ADCETRIS study results for people with certain types of T-cell lymphoma
Previously untreated PTCL
Relapsed pcALCL or MF
Previously untreated peripheral T-cell lymphoma
ADCETRIS is used with chemotherapy (CHP) for the treatment of adults with previously untreated systemic anaplastic large cell lymphoma or other CD30-expressing T-cell lymphoma.
In a large clinical study of 452 people with peripheral T-cell lymphoma, ADCETRIS plus CHP was compared to CHOP, a traditional and more commonly used chemotherapy option.
- 226 people were treated with ADCETRIS plus CHP
- 226 people were treated with CHOP
Select the button above to view side effects.
Main study results
Used to support the FDA approval of ADCETRIS plus CHP. The average follow-up time for the main study was 3.5 years.
At 3 years, 57% of ADCETRIS plus CHP patients were alive without their cancer growing or spreading, or needing additional anticancer therapy, compared to 44% of those treated with CHOP.
Patients lived longer
More people treated with ADCETRIS plus CHP lived longer than those treated with CHOP.
Patients saw tumor size reduced
More people treated with ADCETRIS plus CHP saw their tumors get smaller or become undetectable compared to those receiving CHOP.
Exploratory follow-up at 5 years
The following results are from an exploratory analysis. The study was not designed to find differences between treatment groups at 5 years. Investigators looked at what happened in the study without determining a definitive benefit. Conclusions cannot necessarily be based on this information. The average follow-up time for the exploratory analysis was 5.6 years.
At 5 years, 51% of ADCETRIS plus CHP patients were alive without their cancer growing or spreading, or needing additional anticancer therapy, compared to 43% of those treated with CHOP.
CHOP: A combination of 4 chemotherapies—cyclophosphamide, doxorubicin, vincristine, and prednisone.
CHP: A combination of 3 chemotherapies—cyclophosphamide, doxorubicin, and prednisone.
Complete remission: When all signs of cancer in your body are undetected following treatment.
Partial remission: A decrease in the size of a tumor, or the amount of cancer in your body, following treatment. Some cancer remains.
FDA: Food and Drug Administration.
The science of ADCETRIS treatment
ADCETRIS is not like traditional chemotherapy. It is an antibody drug conjugate made up of 3 parts: an antibody, a drug, and a linker.
An antibody that finds CD30, a protein on the surface of certain cells. Antibodies are proteins made by the body’s immune system. The antibody that makes up ADCETRIS is made in a laboratory.
A drug that is designed to cause cell death.
A linker that attaches the drug to the antibody and releases the drug inside the cell.